Introduction to Diaceutics (350+ Words)

Diaceutics is a pioneering healthcare technology company headquartered in Belfast, Northern Ireland, with additional offices in the United States and Europe. Specializing in the intersection of diagnostics and therapeutics, Diaceutics has established itself as a vital partner for pharmaceutical companies, clinical laboratories, and healthcare providers aiming to accelerate the adoption of precision medicine. The company’s innovative platform, DXRX, integrates real-world diagnostic data, laboratory analytics, and market intelligence to optimize the journey of targeted therapies from clinical trials to patient access. Recognized as a leader in the Healthcare sector, Diaceutics holds a strong market reputation for its data-driven approach, serving over 50 pharmaceutical clients and managing data from more than 1,000 laboratories globally. The company’s scale and expertise allow it to address critical challenges in biomarker testing, therapeutic area coverage, and commercial strategy, making it indispensable for organizations that rely on evidence-based insights to improve patient outcomes. By blending advanced analytics with deep domain knowledge, Diaceutics enables its clients to navigate the complexities of companion diagnostics, regulatory pathways, and reimbursement landscapes.

As a top employer in the Healthcare industry, Diaceutics fosters a culture of innovation, collaboration, and continuous learning. Its workforce includes data scientists, bioinformaticians, commercial strategists, and medical experts who work synergistically to deliver actionable intelligence. The company’s commitment to quality and transparency is reflected in its ISO 27001 certification and adherence to GDPR standards. For professionals seeking to make a tangible impact on global health, Diaceutics offers a dynamic environment where cutting-edge technology meets real-world clinical needs. This introduction sets the stage for understanding why Diaceutics is not just a service provider but a catalyst for change in precision medicine.

Company History and Business Evolution (450+ Words)

Founded in 2009, Diaceutics emerged from the recognition that diagnostic data was vastly underutilized in the pharmaceutical industry. The company’s founders, with backgrounds in diagnostic business intelligence and pharmaceutical commercialization, identified a critical gap: while targeted therapies were becoming more prevalent, the diagnostic infrastructure needed to identify eligible patients was fragmented and opaque. Starting with a small team in Belfast, Diaceutics began by aggregating laboratory data and developing proprietary algorithms to map testing patterns. The early years focused on building a robust data network and proving the value of diagnostic analytics for leading pharma companies.

A pivotal milestone came in 2013 when Diaceutics launched its flagship platform, DXRX, which revolutionized how pharmaceutical companies track biomarker testing rates. This coincided with the rise of immuno-oncology, creating massive demand for precise diagnostic insights. In 2015, the company expanded into the U.S. market, establishing offices in Philadelphia to be closer to major pharmaceutical hubs. Acquisitions played a key role in accelerating growth: in 2018, Diaceutics acquired the health economics and outcomes research (HEOR) division of a prominent consulting firm, enhancing its ability to model patient journeys and cost-effectiveness. The following year, the company went public on the London Stock Exchange's AIM market, raising capital to fuel international expansion and product development.

In 2020, amidst the global pandemic, Diaceutics pivoted to support COVID-19 testing analytics and vaccine distribution strategies, demonstrating its adaptability. Post-pandemic, the company doubled down on artificial intelligence and machine learning to improve predictive modeling. By 2024, Diaceutics achieved a significant milestone: its database included de-identified diagnostic data from over 1,200 laboratories across 30 countries, covering all major therapeutic areas from oncology to neurology. The company’s evolution from a niche data aggregator to a comprehensive precision medicine solutions provider reflects its ability to anticipate market shifts and invest in innovation. Today, Diaceutics is recognized as a trusted partner for the world’s top pharmaceutical companies, and its journey continues with new ventures in real-world evidence and decentralized clinical trials.

Diaceutics at a Glance

• Headquarters: Belfast, Northern Ireland, UK
• Founded: 2009
• CEO: Peter Keeling
• Employees: Approximately 300 (as of 2025)
• Revenue: £35 million (FY 2024)
• Stock Ticker: AIM: DXRX
• Industry: Healthcare Technology / Precision Medicine
• Core Product: DXRX Diagnostic Analytics Platform
• Number of Clients: Over 55 pharmaceutical companies
• Global Reach: Data from 1,200+ laboratories in 30+ countries
• Key Therapeutic Areas: Oncology, Neurology, Rare Diseases, Autoimmune Disorders
• Certifications: ISO 27001, GDPR Compliant
• Office Locations: Belfast, Philadelphia, London, Munich
• Major Partners: Multiple top-20 pharma companies
• Notable Acquisition: HEOR division of a leading consulting firm (2018)
• Annual Data Points Processed: Over 10 million patient-level records
• Awards: Digital Health Awards, Deloitte Fast 50
• Social Impact: Partnered with Patient Advocacy groups for equitable testing
• Product Launches: DXRX-Insights (2022), DXRX-Simulate (2024)
• Focus: Accelerating patient access to targeted therapies through diagnostic intelligence

Mission, Vision, and Core Corporate Values

Mission: To empower the healthcare ecosystem by turning diagnostic data into actionable intelligence, ensuring that every patient who can benefit from a targeted therapy is tested and treated.

Vision: A world where diagnostics and therapeutics are seamlessly integrated, enabling the right treatment for every patient at the optimal time in their care journey.

Core Corporate Values:

• Patient-Centricity: Every decision is made with the ultimate goal of improving patient outcomes. Diaceutics places the patient at the heart of its analytics, ensuring data privacy and ethical usage.
• Innovation: The company fosters a culture of continuous improvement, investing in cutting-edge technologies like AI, machine learning, and real-world evidence generation to stay ahead of industry needs.
• Collaboration: Diaceutics believes that solving complex healthcare challenges requires partnerships. The company works closely with pharmaceutical sponsors, laboratories, and clinicians to co-create solutions.
• Integrity: Transparency and ethical data handling are non-negotiable. Diaceutics adheres to rigorous compliance standards and ensures that all data is de-identified and used responsibly.
• Excellence: The company strives for the highest quality in its products and services, consistently meeting client needs with precision and reliability.

Business Strategy and Future Roadmap

Diaceutics’ business strategy rests on three pillars: Data Network Expansion, Analytics Innovation, and Market Penetration. The company continuously broadens its laboratory network, particularly in emerging markets like Asia-Pacific and Latin America, to capture diverse patient populations and testing practices. By integrating more data sources, Diaceutics enhances its benchmarking capabilities, offering clients a comprehensive view of diagnostic landscapes across regions. In terms of analytics innovation, the company is heavily investing in artificial intelligence to predict testing rates, identify barriers to testing, and simulate the impact of interventions like education campaigns or reimbursement changes. The recent launch of DXRX-Simulate, a predictive modeling tool, exemplifies this focus.

Future roadmap includes expanding into new therapeutic areas such as cardiovascular disease and metabolic disorders, where biomarker testing is becoming increasingly important. Diaceutics also plans to deepen its involvement in decentralized clinical trials, using its data network to identify and recruit patients based on real-world diagnostic histories. Another strategic priority is the development of a ‘Diagnostic Patient Journey’ module, which will map the step-by-step process from symptom presentation to final diagnosis and treatment start. This will help pharmaceutical companies identify bottlenecks and tailor their market access strategies. Additionally, the company is exploring partnerships with electronic health record (EHR) vendors to enrich its data layers with clinical outcomes, enabling more robust real-world evidence generation. Financially, Diaceutics aims to achieve profitability growth through higher-margin software subscription models and cross-selling existing clients additional modules. The long-term vision includes becoming the standard platform for diagnostic intelligence globally, akin to a Bloomberg terminal for precision medicine.

Products, Technologies, and Services

Diaceutics offers a suite of integrated products and services centered around its proprietary DXRX Platform.

• DXRX-Insights: A comprehensive analytics module that provides detailed testing rates, market share by laboratory, and turnaround times for specific biomarkers. It includes dashboards for tracking performance against benchmarks and identifying undertesting regions.
• DXRX-Simulate: A predictive modeling tool that uses machine learning to forecast future testing volumes and assess the impact of various commercial interventions. It helps clients design more effective testing programs.
• DXRX-Companion Diagnostic Strategy: Consulting services that guide pharmaceutical companies in selecting the right diagnostic partner for their drug biomarker, including regulatory approval support and launch planning.
• Real-World Evidence: Generation of evidence from diagnostic data to support health technology assessments (HTA), payer negotiations, and clinical guideline inclusion.
• Laboratory Network Services: Support for laboratories in optimizing their test offerings, improving turnaround times, and participating in clinical trial testing.
• Data Security Solutions: Ensuring end-to-end encryption and compliance with global privacy regulations (GDPR, HIPAA) through robust data governance frameworks.

Technologically, Diaceutics leverages a cloud-based architecture hosted on AWS for scalability and reliability. The platform integrates natural language processing (NLP) to extract structured data from unstructured pathology reports and uses graph databases to map complex relationships between diagnosis codes, drugs, and genetic markers. APIs allow seamless integration with pharmaceutical CRM systems and laboratory information systems (LIS). The company also employs federated learning techniques to enable collaborative analytics without centralizing sensitive patient data.

Industries and Markets Served

Diaceutics primarily serves the Pharmaceutical and Biotechnology industry, but its impact extends to Clinical Laboratories, Diagnostic Manufacturers, and Healthcare Payers. Within pharmaceuticals, the company works with both large multinationals and emerging biotechs specializing in targeted therapies. The key therapeutic areas include:

• Oncology: Testing for biomarkers such as PD-L1, EGFR, ALK, BRAF, and HRD. Diaceutics supports over 90% of the top cancer drugs in development.
• Neurology: Diagnostic analysis for Alzheimer’s disease (amyloid PET, CSF biomarkers) and rare neurological conditions.
• Rare Diseases: Genetic testing for conditions like spinal muscular atrophy and lysosomal storage disorders.
• Autoimmune and Inflammatory Diseases: HLA typing and cytokine level monitoring.

Geographically, the company’s primary markets are North America and Western Europe, but it is expanding aggressively into Asia-Pacific, Latin America, and the Middle East. Emerging markets offer significant growth opportunities due to increasing healthcare digitization and rising demand for targeted therapies. Diaceutics also provides consulting services to public health bodies and national health systems aiming to improve diagnostic infrastructure.

Leadership and Management Philosophy

Diaceutics is led by Peter Keeling, CEO, who previously served as Chief Commercial Officer. Under his leadership, the company has cultivated a flat management structure that encourages open communication and rapid decision-making. The leadership team includes Dr. Jacob Hazel (Chief Scientific Officer), who oversees clinical validation, and Ciara O’Leary (Chief Revenue Officer), who drives commercial strategy. The management philosophy revolves around three tenets: Empowerment – giving employees autonomy to own projects; Data-Driven Decision Making – using internal analytics to guide strategy; and Continuous Learning – investing in professional development, including certifications in machine learning and healthcare compliance. The company holds quarterly all-hands meetings where financial performance and strategic updates are shared transparently. This approach has fostered high employee engagement and low turnover rates compared to industry averages.

Corporate Events, Conferences, and Community Engagement

Diaceutics regularly sponsors and participates in major industry conferences such as AACR (American Association for Cancer Research), ASCO (American Society of Clinical Oncology), DIA Annual Meeting, and BIO International Convention. The company often presents white papers on diagnostic trends and hosts workshops on leveraging real-world data. Additionally, Diaceutics organizes an annual Precision Medicine Summit in Belfast, bringing together pharmaceutical executives, laboratory directors, and health economists to discuss future directions. In terms of community engagement, the company has partnered with Patient Advocacy Groups like the Lung Cancer Foundation and the Alzheimer’s Association to promote equitable access to testing. Diaceutics also runs a CSR program where employees volunteer for STEM education initiatives in local schools, focusing on data science and genetics awareness.

Employees and Workplace Culture

With around 300 employees, Diaceutics prides itself on a diverse and inclusive workplace. The culture emphasizes collaboration across departments, with regular cross-functional ‘Innovation Sprints’ to solve client problems. Flexible working arrangements are standard, with many roles offering remote or hybrid options. The company also provides generous benefits including health insurance, learning stipends, and stock options. Employee satisfaction is high, as evidenced by internal surveys showing 85% agreement with ‘I am proud to work here’. The company actively seeks talent from both healthcare and technology backgrounds, valuing a mix of domain expertise and analytical skills. Career progression is transparent, with clear pathways for promotion based on impact and skill development. Diaceutics also runs an internal ‘Women in Data’ network to support gender diversity in technical roles.

Job Details & Requirements for this Posting (Detailed)

Role: Senior Data Scientist
Location: Belfast, Northern Ireland (Hybrid) or Remote within UK
Salary Range: £70,000 - £95,000 per year (depending on experience) plus benefits
Job Type: Full-time

Responsibilities:

• Design and implement machine learning models to predict patient testing rates, identify demographic and regional barriers, and forecast market dynamics for companion diagnostics.
• Analyze large-scale, real-world diagnostic datasets comprising millions of records to extract actionable insights for pharmaceutical clients.
• Develop and maintain data pipelines for ingesting, cleaning, and structuring data from diverse sources (laboratory information systems, claims data, pathology reports).
• Collaborate with product managers and life science experts to translate business questions into analytical frameworks.
• Present findings to internal and external stakeholders through clear visualizations and reports.
• Mentor junior data scientists and contribute to best practices in code quality, reproducibility, and documentation.
• Stay current with advances in AI/ML, particularly as applied to healthcare and genomics.

Qualifications:

• Master’s or PhD in Data Science, Computer Science, Statistics, or a related quantitative field (PhD preferred).
• 5+ years of experience in data science, with at least 2 years in healthcare or life sciences.
• Proficiency in Python, SQL, and machine learning libraries (scikit-learn, TensorFlow, PyTorch).
• Experience with cloud platforms (AWS or Azure) and big data tools (Spark, Airflow).
• Knowledge of healthcare data standards (ICD-10, LOINC, SNOMED) and privacy regulations (GDPR, HIPAA) is a plus.
• Strong communication skills and ability to work in a fast-paced, client-facing environment.

Why Join Diaceutics?

• Impact: Directly contribute to expanding patient access to life-saving therapies.
• Growth: Be part of a high-growth company trading on AIM with opportunities for rapid advancement.
• Culture: Work with a passionate team dedicated to innovation and data ethics.
• Benefits: Competitive salary, bonus scheme, private healthcare, pension, and learning budget.
• Flexibility: Hybrid or remote options available for UK-based candidates.

Customer Reviews and Industry Reputation (1200+ Words)

Diaceutics has garnered a strong reputation across multiple review platforms, reflecting both its product quality and corporate culture. Below is an exhaustive analysis based on aggregated reviews.

GLASS DOOR

On Glassdoor, Diaceutics holds an overall rating of 4.2 out of 5 stars based on 200+ reviews. Employees praise the company’s flexible working environment, especially the remote-first policy. Common positive themes include ‘collaborative culture’, ‘innovative projects’, and ‘strong management support’. Many reviewers highlight the company’s transparency in financial updates and career development opportunities. For example, one data analyst commented, “I have grown more here in two years than I would have in five years elsewhere.” Constructive feedback often mentions high workload during peak client periods and occasional cross-timezone challenges. The CEO has a 95% approval rating from employees, indicating trust in leadership. Overall, Glassdoor reviews paint a picture of a company that values its workforce and is committed to growth.

INDEED

Indeed reviews from current and former employees give Diaceutics a 4.0 rating. Employees frequently cite the ‘meaningful mission’ and ‘great colleagues’ as strengths. Some reviews from the US office note that the company is rapidly expanding, which can lead to growing pains but also creates opportunities for lateral moves and promotions. The most common praise is for the data-driven culture and the use of modern tooling like Snowflake and AWS. Criticisms are relatively mild, centering on the need for more structured onboarding. An Indeed review from a senior data scientist stated: “The work is challenging in a good way. I feel my contributions directly impact how drugs get to patients.”

GARTNER PEER INSIGHTS

On Gartner Peer Insights, Diaceutics is recognized as a niche player in the healthcare analytics space, with an average rating of 4.1 out of 5. Users, primarily pharmaceutical executives, appreciate the platform’s ability to deliver granular insights on lab testing that are not available from other vendors. One reviewer noted: “DXRX-Insights gave us a clear map of which labs were testing, which weren’t, and why. This was critical for our launch strategy.” However, some users wished for more frequent data refreshes and deeper integration with electronic medical records. Overall, the sentiment is positive, with the majority of reviewers recommending Diaceutics.

TRUSTPILOT

Trustpilot reviews are generally favorable, with a 4.3 out of 5 rating from over 500 reviews. Customers highlight the helpfulness of the support team and the flexibility of the analytics platform. Many client testimonials emphasize that Diaceutics’ insights led to measurable improvements in testing rates. A typical review read: “We used DXRX-Simulate to run a pilot education program, and within six months, testing rates in that region increased by 22%. The team was responsive and customized the tool to our needs.” Negative reviews are rare and often relate to minor integration issues that were quickly resolved.

G2

On G2, Diaceutics is categorized under ‘Healthcare Analytics’ and has a 4.2 rating. Users praise the user interface and the depth of data visualizations. The platform is described as ‘intuitive’ and ‘feature-rich’. One reviewer from a top-10 pharma company commented: “The pre-built dashboards on biomarker testing saved us weeks of manual work. We now use it quarterly to monitor our testing strategy.” Some feedback indicates that the initial learning curve can be steep for users without analytics backgrounds. G2 also highlights Diaceutics’ responsiveness to feature requests, with many users noting that requested enhancements were implemented within months.

GOOGLE REVIEWS

Google Reviews for Diaceutics, while limited, show a 4.4 average. Reviews often come from event attendees (e.g., Diaceutics-hosted webinars) who appreciate the thought leadership. One review stated: “Attended their precision medicine summit, and the insights were top-notch. Great networking event.” Employee reviews on Google also reflect a positive work environment, with words like ‘inspiring’ and ‘innovative’ frequently used.

LINKEDIN REPUTATION

On LinkedIn, Diaceutics enjoys a strong follower base of over 50,000. The company’s page is active with regular posts about industry news, employee spotlights, and product updates. The ‘Life’ section features employee testimonials and behind-the-scenes content, which helps attract talent. Professional network ratings are not standardized, but the high engagement (comments, shares) on posts indicates strong brand affinity. Many industry influencers and thought leaders follow Diaceutics, boosting its credibility. A LinkedIn poll conducted by a pharma analytics group showed that 78% of respondents would recommend Diaceutics as a vendor.

Why Organizations Choose Diaceutics

Organizations choose Diaceutics for several compelling reasons. First, the company offers the largest proprietary dataset of diagnostic testing data, covering hundreds of biomarkers across 30+ countries. This breadth provides a level of granularity that competitors cannot match. Second, the platform’s predictive capabilities (DXRX-Simulate) allow clients to proactively plan interventions rather than reacting to market changes. Third, Diaceutics provides deep domain expertise through its team of scientists and former pharmaceutical executives, ensuring that analytics are contextually relevant. Fourth, the company’s commitment to data security and regulatory compliance (ISO 27001, GDPR) gives clients confidence in handling sensitive patient data. Finally, the high-touch customer support, including dedicated account managers and quarterly business reviews, fosters long-term partnerships.

Official Contact Information

For inquiries and assistance, please reach out to Diaceutics using the following contact details:

Address: Diaceutics Ltd, The Linenhall 32 Linenhall Street, Belfast BT2 8BG, United Kingdom
Contact Number: +44 (0)28 9099 6400
Support Number: +1 855 456 7890 (for US clients)
Helpdesk Number: +44 (0)28 9099 6401
Website: https://www.diaceutics.com/

Official Social Media Presence

• LinkedIn
• Twitter (X)
• YouTube
• Company Blog

SEO FAQ Section

Diaceutics is known for its DXRX platform that provides diagnostic analytics and intelligence for precision medicine, helping pharmaceutical companies optimize patient testing for targeted therapies.

Diaceutics is headquartered in Belfast, Northern Ireland, with additional offices in the United States and Europe.

Diaceutics employs approximately 300 people globally across its offices.

The CEO of Diaceutics is Peter Keeling.

The main product of Diaceutics is the DXRX platform, which encompasses modules like DXRX-Insights and DXRX-Simulate for diagnostic data analysis.

Yes, Diaceutics is listed on the London Stock Exchange’s AIM market under the ticker DXRX.

Diaceutics primarily serves the pharmaceutical, biotechnology, clinical laboratory, and healthcare payer industries.

Diaceutics follows ISO 27001 standards, complies with GDPR and HIPAA, and uses de-identification techniques to protect patient data.

Yes, Diaceutics offers consulting services to guide pharmaceutical companies in selecting diagnostic partners and navigating regulatory approvals.

Diaceutics covers oncology, neurology, rare diseases, and autoimmune/inflammatory conditions.

Yes, Diaceutics supports hybrid and remote work options for many roles, especially in the UK and US offices.

Diaceutics reported revenue of approximately £35 million for the fiscal year 2024.

Diaceutics has data partnerships with over 1,200 laboratories across 30 countries.

Diaceutics analyzes real-world diagnostic data, including testing rates, turnaround times, and biomarker prevalence from pathology reports and laboratory information systems.

Yes, Diaceutics uses machine learning and natural language processing to enhance predictive analytics and data extraction.

Diaceutics holds ISO 27001 certification and is GDPR compliant.

Job openings at Diaceutics are posted on the official website under ‘Careers’ and on LinkedIn.

Diaceutics promotes a collaborative, data-driven culture with flexible working and opportunities for continuous learning.

Yes, Diaceutics regularly attends and speaks at major conferences like AACR, ASCO, DIA, and BIO International.

Diaceutics differentiates itself through its vast proprietary diagnostic dataset, predictive modeling tools, and deep domain expertise in precision medicine commercialization.

Explore more insights and discover how Diaceutics can transform your precision medicine strategy. For those seeking to enhance their digital presence, leveraging Guest Post Outreach Services can boost visibility. Visit Houston News Buzz for effective guest posting solutions that complement your business growth.